Article info
PDFState of the art review
COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms
- Correspondence to Dr Michael Newnham, Institute of Applied Health Research, University of Birmingham, Birmingham, UK; m.newnham{at}bham.ac.uk
Citation
COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms
Publication history
- Received September 22, 2020
- Revised October 30, 2020
- Accepted November 11, 2020
- First published January 6, 2021.
Online issue publication
September 01, 2022
Article Versions
- Previous version (15 March 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage